PMID- 26111953
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20220316
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 24
IP  - 2
DP  - 2016 Feb
TI  - Xerosis and pruritus as major EGFRI-associated adverse events.
PG  - 513-521
LID - 10.1007/s00520-015-2781-y [doi]
AB  - PURPOSE: The objective of this sub-analysis of the BeCet study (NCT01136005) was 
      to examine health-related quality of life (HRQoL) of patients experiencing 
      dermatological adverse events (AEs) during the first 6 weeks of epidermal growth 
      factor receptor inhibitor (EGFRI) treatment. METHODS: Patients (n = 85) treated 
      with EGFRI completed five questionnaires during the first 6 weeks of treatment. 
      77 patients provided enough data for the sub-analysis. Experienced AEs were 
      reported in the Dermatological Reactions Targeted Therapy-Patients (DERETT-P), a 
      symptom experience diary for patients treated with targeted therapy. The impact 
      of EGFRI-associated dermatological adverse events on HRQoL was examined using 
      four HRQoL questionnaires; the Functional Assessment of Cancer Therapy-EGFRI 
      (FACT-EGFRI-18), the Functional Assessment of Cancer Therapy-General (FACT-G), 
      the 36-Item Short Form Health Survey (SF-36), and the Skindex-16. RESULTS: During 
      the first 6 weeks of EGFRI treatment, physical discomfort was the most 
      significantly affected domain. In the entire study population, xerosis (dry skin) 
      (22.3 %) and pruritus (itchy skin) (16.9 %) were reported as the most impactful 
      AEs. For patients experiencing a papulopustular eruption (acneiform rash) 
      pruritus (24.2 %), xerosis (18.9 %), and papulopustular eruption (6.3 %) were 
      reported as the most impactful AEs. Papulopustular eruption, xerosis, and 
      pruritus all showed a significant negative effect on HRQoL, displayed in 
      FACT-EGFRI-18 scores. CONCLUSIONS: In addition to papulopustular eruption, 
      xerosis and pruritus are major EGFRI-associated dermatological AEs with an impact 
      on HRQoL, which warrant more attention in clinical practice and research.
FAU - Clabbers, Julia M K
AU  - Clabbers JMK
AD  - Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 
      2300 RC, Leiden, The Netherlands. juliamkclabbers@gmail.com.
FAU - Boers-Doets, Christine B
AU  - Boers-Doets CB
AD  - Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 
      2300 RC, Leiden, The Netherlands.
FAU - Gelderblom, Hans
AU  - Gelderblom H
AD  - Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 
      2300 RC, Leiden, The Netherlands.
FAU - Stijnen, Theo
AU  - Stijnen T
AD  - Department of Medical Statistics and Bioinformatics, Leiden University Medical 
      Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Department of Medicine, Dermatology Service, Memorial Sloan-Kettering Cancer 
      Center, New York, NY, 10065, USA.
FAU - van der Hoeven, Koos J M
AU  - van der Hoeven KJM
AD  - Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 
      2300 RC, Leiden, The Netherlands.
FAU - Kaptein, Adrian A
AU  - Kaptein AA
AD  - Department of Medical Psychology, Leiden University Medical Centre, P.O. Box 
      9600, 2300 RC, Leiden, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT01136005
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150627
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Drug Eruptions/drug therapy/*psychology
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Exanthema/chemically induced/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/drug therapy
MH  - Pruritus/chemically induced/*psychology
MH  - Quality of Life/*psychology
MH  - Surveys and Questionnaires
PMC - PMC4689742
OTO - NOTNLM
OT  - Cancer
OT  - Epidermal growth factor receptor inhibitor
OT  - Papulopustular eruption
OT  - Pruritus
OT  - Quality of life
OT  - Xerosis
EDAT- 2015/06/27 06:00
MHDA- 2016/08/16 06:00
PMCR- 2015/06/27
CRDT- 2015/06/27 06:00
PHST- 2014/11/17 00:00 [received]
PHST- 2015/05/17 00:00 [accepted]
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
PHST- 2015/06/27 00:00 [pmc-release]
AID - 10.1007/s00520-015-2781-y [pii]
AID - 2781 [pii]
AID - 10.1007/s00520-015-2781-y [doi]
PST - ppublish
SO  - Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 
      2015 Jun 27.